Compare Marathon Petroleum Corp (MPC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs BIO-TECHNE Corp — how do they compare? Marathon Petroleum Corp trades at $462.2 (market cap $124.20B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Marathon Petroleum Corp is far larger — about 10.9× BIO-TECHNE Corp's market cap, and Marathon Petroleum Corp pays the higher dividend (0.9%). Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 54 Days and BIO-TECHNE Corp for 63 Days on average.
| MPC | TECH | |
|---|---|---|
Market Cap | $124.20B | $11.37B |
Volume | 1,923,373 | 3,153,511 |
Sector | Energy | Health |
52-Week High | $463.34 | $72.61 |
52-Week Low | $162.63 | $43.31 |
Typical Hold Time | 54 Days | 63 Days |
Enterprise Value | $150.72B | $11.40B |
Dividend Yield | 0.9% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $463.34, up 7.17% over 24 hours and near its 52-week high. The stock exhibits strong bullish momentum with consistent earnings beats and robust profitability metrics, including a 47.9% ROE. Recent news highlights refining margin strength amid tight global capacity, though potential diesel export curbs pose a risk. Technical indicators show bullish moving averages but an overbought RSI, with key resistance at $452.
MPC presents a compelling investment case with solid fundamentals, high analyst buy ratings (75.76%), and a consensus price target of $420.30. Upside is driven by elevated refining margins and earnings growth, but risks include regulatory threats to exports and volatile energy markets. The stock's current premium to target suggests cautious optimism amid near-term overbought conditions.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
